Skip to main content

Table 2 Comparison of mouseMAPS in homogenates of untreated or GLV-1h68-treated HCT-116 tumors

From: Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68

Antigen

Untreated

GLV-1h68

P value

Ratio

CD40

31.87 ± 10.5 fg/mg

193.41 ± 27.53 fg/mg

**

6.1

Eotaxin

1.24 ± 0.67 fg/mg

371.48 ± 122.26 fg/mg

*

300.0

GCP-2 mouse

0.03 ± 0.009 pg/mg

0.50 ± 0.29 pg/mg

*

19.3

KC/GRO

0.002 ± 0.001 pg/mg

0.073 ± 0.018 pg/mg

**

34.9

IFN gamma

1.61 ± 0.03 fg/mg

7.21 ± 0.35 fg/mg

***

4.5

IP-10

2.20 ± 0.71 fg/mg

145.28 ± 27.64 fg/mg

**

66.2

IL-1 alpha

14.18 ± 2.02 fg/mg

78.76 ± 7.82 fg/mg

***

5.6

IL-3

0.082 ±0.018 fg/mg

0.45 ± 0.18 fg/mg

*

5.5

IL-6

1.63 ± 0.57 fg/mg

20.24 ± 12.76 fg/mg

 

12.5

IL-10

9.89 ± 1.68 fg/mg

52.48 ± 0.46 fg/mg

***

5.3

IL-11

6.03 ± 1.70 fg/mg

41.71 ± 9.32 fg/mg

**

6.9

IL-17A

5.20 ± 0.93 fg/mg

52.96 ± 6.40 fg/mg

***

10.2

IL-18

1.41 ± 0.08 pg/mg

8.03 ± 2.33 pg/mg

*

5.7

Lymphotactin

14.25 ± 3.87 fg/mg

235.25 ± 36.29 fg/mg

***

16.5

M-CSF-1

318.57 ± 7.40 fg/mg

122.67 ± 35.91 fg/mg

**

38.5

MIP-1 beta

25.70 ± 8.90 fg/mg

1286.62 ± 206.46 fg/mg

***

50.1

MIP-2

1.20 ± 0.38 fg/mg

65.92 ± 30.24 fg/mg

*

55.1

MIP-3

0.065 ± 0.01 fg/mg

0.36 ± 0.03 fg/mg

***

5.5

MMP-9

9.93 ± 7.02 pg/mg

91.31 ± 60.77 pg/mg

 

9.2

MCP-1

14.55 ± 4.65 fg/mg

3332.49 ± 93.80 fg/mg

***

229.1

MCP-3

18.20 ± 7.64 fg/mg

2023.74 ± 386.90 fg/mg

***

111.2

MCP-5

11.91 ± 6.71 fg/mg

676.99 ± 187.73 fg/mg

**

56.8

RANTES

0.0052 ± 0.003 fg/mg

0.54 ± 0.11 fg/mg

**

105.7

TIMP-1 mouse

1.30 ± 0.22 pg/mg

12.22 ± 4.53 pg/mg

*

9.36

TNF alpha

5.38 ± 0.59 fg/mg

23.01 ± 2.51 fg/mg

***

4.27

FGF-b

107.94 ± 16.12 pg/mg

69.86 ± 15.26 pg/mg

*

1.5

MIP-1 alpha

0.23 ± 0.008 pg/mg

0.13 ± 0.034 pg/mg

*

1.7

MIP-1 gamma

0.94 ± 0.15 pg/mg

0.30 ± 0.03 pg/mg

**

3.1

SGOT

2.08 ± 0.72 pg/mg

1.08 ± 0.56 pg/mg

 

1.9

  1. The table compares the levels of mouse immune-related protein antigen profiling in homogenates of untreated and GLV-1h68-treated HCT-116 tumors normalized to total protein per sample 21 days after virus injection [n=3]. The ratio of antigen in GLV-1h68-treated and untreated animals and the level of statistical significance are shown. * = P≤0.05, ** = P≤0.005, *** = P≤0.0005.